Roivant Sciences highlights pipeline progress at Investor Day

Roivant is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company’s strategy for long-term value creation. Brepocitinib: Preparation for commercial launch of brepocitinib in DM is underway; NDA filing expected in early calendar year 2026 with potential commercial launch early in calendar year 2027; Phase 3 trial for brepocitinib in NIU is fully enrolled ahead of schedule with topline data expected in the second half of calendar year 2026, previously expected in the first half of calendar year 2027; Proof-of-concept trial for brepocitinib in CS is fully enrolled ahead of schedule with topline data expected in the first half of calendar year 2026, previously expected in the second half of calendar year 2026. IMVT-1402: Roivant-led Immunovant financing alongside key institutional investors generated gross proceeds to Immunovant of approximately $550M, extending Immunovant’s cash runway to the launch of IMVT-1402 in GD; Potentially registrational trial for IMVT-1402 in D2T RA topline data now expected in calendar year 2026; previously expected Period 1 data in calendar year 2026 and topline data in calendar year 2027; All other clinical development timelines remain on track, including potentially registrational trials in GD, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjogren’s disease, and a proof-of-concept trial in cutaneous lupus erythematosus. Mosliciguat: Enrollment in the ongoing Phase 2 trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease remains on track; Pulmovant plans to report topline data in the second half of calendar year 2026; Pulmovant also expects to imminently initiate a Phase 2 study evaluating mosliciguat in combination with inhaled treprostinil in patients with PH-ILD. Genevant; In the US Moderna litigation, a jury trial has been scheduled for March 2026. Awaiting court scheduling in the Pfizer/BioNTech litigation; Initial court hearings and rulings in the ex-US Moderna litigation expected in calendar year 2026.